EASD KOL Perception Study · Diabetes

EASD KOL Perception Study: How Diabetes Experts View Scientific Value, Clinical Influence and Future Opportunities

The diabetes treatment landscape is evolving rapidly, driven by new clinical evidence, emerging therapies, novel mechanisms of action and increasingly complex treatment decisions. In this environment, scientific congresses remain important platforms through which healthcare professionals access new evidence, exchange perspectives and understand diabetes treatment trends.

Diabetes N=25 KOLs EASD KOL Research Scientific Value
25KOLs
Study focus Scientific value, content relevance, clinical influence, competitive positioning and future opportunities.
88% Scientific value High / Very high
80% Emerging treatments Highly influential
68% Clinical thinking High / Very high influence
84% Scientific positioning Leading diabetes congress

EASD’s Role in the Changing Diabetes Evidence Landscape

The diabetes treatment landscape is evolving rapidly, driven by new clinical evidence, emerging therapies, novel mechanisms of action and increasingly complex treatment decisions. In this environment, scientific congresses remain important platforms through which healthcare professionals access new evidence, exchange perspectives and understand diabetes treatment trends.

This EASD KOL Perception Study examined how 25 diabetes KOLs perceive EASD across scientific value, content relevance, clinical influence, competitive positioning and future opportunities.

The Diabetes KOL perception study included diabetologists, endocrinologists and diabetes specialists who participated in structured KOL interviews/questionnaires. The findings indicate that EASD has strong scientific credibility, while also revealing an opportunity to strengthen the connection between scientific evidence and practical clinical application.

Study at a Glance

  • Study type: Primary market research
  • Sample: 25 diabetes KOLs
  • Respondents: Diabetologists, endocrinologists and diabetes specialists
  • Method: Structured KOL interviews/questionnaire
  • Focus: Scientific value, content relevance, clinical influence and future opportunities

Source: Primary KOL research, n=25. Findings represent the perceptions of surveyed respondents and should not be interpreted as representative of all EASD attendees or the broader diabetes specialist population.


What Is the Scientific Value of EASD According to Diabetes KOLs?

The strongest finding from the EASD perception study is the high level of scientific value attributed to the congress.

22 of 25 KOLs (88%) rated EASD’s scientific value as high or very high.

The factors most valued by respondents included:

  • High-quality diabetes research
  • Credibility of presented data
  • Emerging scientific evidence
  • Access to leading international experts

The findings demonstrate strong EASD scientific value among diabetes KOLs and suggest that scientific credibility remains one of the congress's most important assets.

For pharmaceutical companies, medical affairs teams and healthcare organizations, this level of scientific equity can make EASD an important environment for understanding how experts interpret new evidence and evolving treatment landscapes.


Why Do Diabetes KOLs Attend or Follow EASD?

The Diabetes KOL survey shows that scientific learning is the primary driver of engagement with EASD.

Engagement Driver KOLs
New clinical trial data 73%
Emerging scientific evidence 71%
Expert presentations and discussions 69%
Peer-to-peer scientific exchange 64%
Treatment updates 58%

New clinical trial data ranked highest, followed closely by emerging scientific evidence.

This indicates that KOL perspectives on EASD are strongly connected to access to credible, timely and scientifically meaningful information rather than simply the volume of available content.

For organizations conducting diabetes market research, this distinction is important. The value of a scientific platform increasingly depends on whether it helps experts identify meaningful evidence and understand its implications.


How Does EASD Influence Understanding of Emerging Diabetes Treatments?

20 of 25 KOLs (80%) considered EASD highly influential in shaping their understanding of emerging diabetes treatments.

Respondents highlighted EASD's role in helping them understand:

  • New clinical evidence
  • Emerging treatment approaches
  • Clinical trial findings
  • New mechanisms and technologies
  • Expert interpretation of scientific developments

This makes EASD an important source of EASD treatment insights and early perspectives on where diabetes research and treatment may be heading.

The findings also demonstrate the EASD impact on emerging diabetes treatments from an information and scientific interpretation perspective.

For diabetes specialists, exposure to emerging evidence can influence further investigation, professional discussions and the way new therapeutic developments are evaluated.


Does EASD Influence Clinical Thinking?

Scientific awareness does not automatically translate into changes in clinical thinking. The study therefore examined the EASD influence on clinical thinking separately.

17 of 25 KOLs (68%) reported that EASD had a high or very high influence on their clinical thinking.

The areas of influence included:

  • Treatment evidence
  • Emerging therapies
  • Peer discussions
  • Clinical perspectives
  • Areas requiring further investigation

The difference between EASD's 80% influence on understanding emerging treatments and 68% influence on clinical thinking provides an important insight.

EASD appears particularly strong at informing scientific understanding, while there remains an opportunity to strengthen the pathway from:

Evidence → Interpretation → Clinical application

This could also support greater EASD influence on diabetes treatment decisions as scientific evidence becomes increasingly connected to practical clinical scenarios.


What EASD Content Do Diabetes KOLs Value Most?

The study found that KOLs place the greatest value on high-impact clinical evidence.

Content Type KOLs
Late-breaking clinical data 76%
Major clinical trial presentations 72%
Expert scientific discussions 68%
Emerging treatment symposia 60%
Guideline/recommendation updates 56%
Real-world evidence 48%
Practical clinical cases 44%

Late-breaking clinical data was the most valued content category, followed by major clinical trial presentations.

This reinforces the importance of evidence quality in shaping EASD content relevance among KOLs.

At the same time, the lower scores for practical clinical cases and real-world evidence indicate potential opportunities to complement research-focused content with greater evidence-to-practice interpretation.


How Do Diabetes KOLs Position EASD Against Other Diabetes Congresses?

21 of 25 KOLs (84%) positioned EASD as a leading scientific diabetes congress.

Its primary strengths were perceived to be:

  • Scientific credibility
  • Research depth
  • Clinical data quality
  • International faculty
  • Access to emerging evidence

This supports the findings of the EASD diabetes congress perception study and highlights strong competitive positioning within the diabetes scientific ecosystem.

However, KOLs also identified areas where EASD could strengthen differentiation:

  • Practical clinical application
  • Real-world evidence
  • Digital engagement
  • Year-round scientific interaction

The findings therefore provide a useful perspective on EASD competitive positioning and how its scientific leadership could be extended beyond the congress itself.


What Future Opportunities Do Diabetes KOLs Identify for EASD?

The research indicates that KOLs are not simply asking for more content. They want more useful interpretation and continued scientific engagement.

Opportunity KOLs
More practical interpretation of evidence 60%
Greater post-congress engagement 52%
More real-world evidence 48%
More interactive expert discussions 44%
More digital/on-demand content 40%

The leading opportunity was more practical interpretation of evidence, selected by 60% of respondents.

This suggests that future value creation could focus on helping specialists understand what new evidence means in real clinical settings.

Potential approaches include:

  • Post-congress evidence summaries
  • Expert-led interpretation of major trial findings
  • Real-world clinical case discussions
  • Interactive scientific exchanges
  • On-demand expert content
  • Year-round scientific engagement

Such approaches could help translate scientific strength into greater practical relevance.


Industry Insight: From Scientific Information to Evidence Interpretation

The findings from this Diabetes KOL perception study reflect a broader shift across healthcare and life sciences.

Healthcare professionals now have access to an enormous volume of scientific information through congresses, publications, clinical trials, digital platforms and medical education.

The challenge is increasingly not access to information, but identifying, interpreting and applying the most relevant evidence.

For pharmaceutical and medical affairs organizations, this creates several important implications.

Understanding Diabetes experts perception of EASD can help stakeholders identify:

  • Which evidence experts consider most valuable
  • How KOLs interpret emerging clinical data
  • Which scientific gaps remain important
  • What drives engagement with scientific congresses
  • How evidence may influence clinical perspectives
  • What type of post-congress engagement KOLs value

This is where structured diabetes scientific congress market research, KOL perception research and scientific engagement intelligence can provide actionable insights.


Five Key Insights From the EASD KOL Study

1. EASD has strong scientific equity.
88% of surveyed KOLs rated its scientific value as high or very high.

2. New evidence is the primary engagement driver.
Clinical trial data and emerging scientific evidence were the leading reasons KOLs follow EASD.

3. EASD strongly influences understanding of emerging treatments.
80% of respondents considered EASD highly influential in understanding emerging diabetes treatments.

4. Clinical influence remains significant but has room to grow.
68% reported high or very high influence on their clinical thinking.

5. Interpretation and continued engagement represent the strongest opportunities.
Practical evidence interpretation and post-congress engagement were the two highest-rated future opportunities.


Frequently Asked Questions

What is an EASD KOL Perception Study?

An EASD KOL Perception Study evaluates how diabetes experts perceive EASD in terms of scientific value, content relevance, clinical influence, competitive positioning and future opportunities.

How many KOLs participated in the study?

The study included 25 diabetes KOLs, including diabetologists, endocrinologists and diabetes specialists.

What percentage of KOLs rated EASD's scientific value highly?

88% of respondents, or 22 out of 25 KOLs, rated EASD's scientific value as high or very high.

How influential is EASD for emerging diabetes treatments?

80% of surveyed KOLs considered EASD highly influential in shaping their understanding of emerging diabetes treatments.

Does EASD influence clinical thinking?

Yes. 68% of respondents reported high or very high influence on their clinical thinking.

What EASD content do KOLs value most?

Late-breaking clinical data was the most valued content, selected by 76% of respondents, followed by major clinical trial presentations at 72%.

How do KOLs perceive EASD compared with other diabetes congresses?

84% of respondents positioned EASD as a leading scientific diabetes congress, citing scientific credibility, research depth and clinical data quality as key strengths.

What is the biggest opportunity identified by diabetes KOLs?

The leading opportunity was more practical interpretation of evidence, identified by 60% of respondents.


Conclusion

The findings from this EASD KOL Perception Study demonstrate that EASD has strong scientific credibility and a leading position among the surveyed diabetes specialists.

Its core strengths—high-quality research, credible clinical data, expert scientific discussion and access to emerging evidence—continue to make it valuable to diabetes KOLs.

However, the research also reveals an important evolution in expert expectations. The next opportunity is not necessarily to deliver more scientific information, but to make high-value evidence more interpretable, actionable and connected to clinical practice.

For EASD, pharmaceutical companies, medical affairs teams and healthcare stakeholders, this creates a clear strategic direction: strengthen the connection between scientific evidence, KOL perspectives and clinical application.

As diabetes treatment trends continue to evolve, organizations that can effectively understand and respond to Diabetes KOL insights and perspectives will be better positioned to identify emerging opportunities, evidence gaps and changing expectations across the diabetes treatment landscape.

Looking to understand diabetes KOL perspectives, scientific priorities and emerging opportunities around EASD?

Use KOL perception research to understand scientific value, evidence relevance, clinical influence, competitive positioning and opportunities for stronger year-round scientific engagement.

SCIENTIFIC VALUE → EVIDENCE INTERPRETATION → CLINICAL INFLUENCE → KOL ENGAGEMENT → FUTURE OPPORTUNITIES
Thought Leadership

Trusted by Industry Leaders

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.

SPER-Astellas Pharma
SPER-Microsoft
SPER-EY
SPER-McKinsey
SPER-Bain
SPER-Max-Healthcare
SPER-DHL
SPER-IQVIA
SPER-Mitsubishi Logistics
SPER-PACCOR
SPER-Macmillan Education
SPER-Kankar IMRB
SPER-ITA
SPER-PWC
SPER-SAPTCA
SPER-Straumann
SPER-Danaher
SPER-AandM
SPER-MENARINI Silicon Biosystems
SPER-IPSOS
SPER-Heineken
HIPPA Compliant
GDPR Certified
ISO 27001
Peer Reviewed
Get Started Today

Your Competitive Advantage in
Pharmaceutical & Medical Technology
Markets

Join industry leaders leveraging AI-powered intelligence to make confident, data-driven decisions that accelerate breakthrough treatments and technologies to market.

No Credit Card Required
15-Minute Demo
Expert Guidance